CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cardiff Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.89−0.02 (-1.71%)
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.2%
19M of 78M shares
Institutional holders
104
20 new, 31 sold out
Net institutional buying
-6M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $1.12M
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRDF | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Laurion Capital Management LP | 3,098,299 | 3.98% | $4.03M | +451,561 | 0.10% |
| Vanguard Capital Management LLC | 2,895,592 | 3.72% | $3.76M | +39,626 | 0.00% |
| Pfizer Inc | 2,411,575 | 3.10% | $3.01M | – | 1.77% |
| Franklin Resources Inc | 1,205,803 | 1.55% | $1.57M | – | 0.00% |
| BlackRock, Inc. | 972,873 | 1.25% | $1.26M | −3,008,514 | 0.00% |
| Blair William & Co/Il | 912,513 | 1.17% | $1.19M | −9,894 | 0.00% |
| Geode Capital Management, LLC | 820,062 | 1.05% | $1.07M | −779,601 | 0.00% |
| UBS Group AG | 638,699 | 0.82% | $830.31K | +238,123 | 0.00% |
| Jane Street Group, LLC | 607,900 | 0.78% | $790.27K | +567,795 | 0.00% |
| Vanguard Fiduciary Trust Co | 410,602 | 0.53% | $533.78K | −35,623 | 0.00% |
| Aqr Capital Management LLC | 346,353 | 0.45% | $450.26K | +280,197 | 0.00% |
| State Street Corp | 331,395 | 0.43% | $430.81K | −855,552 | 0.00% |
| Hrt Financial LP | 272,786 | 0.35% | $354 | New | 0.00% |
| Flputnam Investment Management Co | 247,474 | 0.32% | $321.72K | −347,653 | 0.00% |
| Morgan Stanley | 246,095 | 0.32% | $319.92K | +189,789 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 228,461 | 0.29% | $297.00K | +215,385 | 0.00% |
| X-Square Capital, LLC | 205,700 | 0.26% | $267 | New | 0.07% |
| Gsa Capital Partners Llp | 173,274 | 0.22% | $225 | +50,266 | 0.01% |
| Marshall Wace, Llp | 162,214 | 0.21% | $210.88K | New | 0.00% |
| Bank of New York Mellon Corp | 161,689 | 0.21% | $210.20K | −141,739 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 104 | 19M | 24.2% | 20 / 35 | 26 / 31 | 3M | 9M |
| Q1 2026 | 117 | 25M | 31.6% | 23 / 30 | 37 / 14 | 5M | 4M |
| Q4 2025 | 110 | 27M | 35.0% | 17 / 25 | 34 / 18 | 4M | 2M |
| Q3 2025 | 112 | 25M | 32.4% | 19 / 33 | 29 / 20 | 3M | 7M |
| Q2 2025 | 114 | 29M | 37.1% | 18 / 45 | 23 / 19 | 6M | 9M |
| Q1 2025 | 116 | 32M | 41.6% | 17 / 49 | 17 / 17 | 8M | 3M |
| Q4 2024 | 117 | 28M | 36.1% | 37 / 39 | 17 / 3 | 17M | 1M |
| Q3 2024 | 83 | 13M | 16.4% | 9 / 25 | 24 / 15 | 4M | 2M |
| Q2 2024 | 90 | 13M | 16.9% | 29 / 33 | 12 / 16 | 7M | 2M |
| Q1 2024 | 77 | 9M | 11.3% | 28 / 17 | 10 / 6 | 4M | 0M |
| Q4 2023 | 55 | 5M | 6.8% | 7 / 9 | 13 / 7 | 0M | 0M |
| Q3 2023 | 55 | 5M | 6.9% | 7 / 8 | 15 / 4 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CRDF | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,073,126 | 2.66% | $2.70M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 759,321 | 0.98% | $987.12K | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 438,961 | 0.56% | $375.49K | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 363,388 | 0.47% | $690.44K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 324,898 | 0.42% | $617.31K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 221,689 | 0.28% | $288.20K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 114,137 | 0.15% | $216.86K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 100,743 | 0.13% | $191.41K | 0.00% | May 31, 2026 |
| Small Company Growth Portfolio | 72,057 | 0.09% | $93.67K | 0.01% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 46,242 | 0.06% | $60.11K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 35,418 | 0.05% | $46.04K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 34,646 | 0.04% | $65.83K | 0.00% | May 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 30,591 | 0.04% | $26.17K | 0.00% | Jul 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 28,295 | 0.04% | $53.76K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 27,727 | 0.04% | $36.05K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mani Mohindru | Chief Executive Officer, Director | 59,067 | 0.08% | Jul 16, 2026 |
| Mark Erlander | Chief Executive Officer, Director | 24,481 | 0.03% | Mar 13, 2025 |
| Ajay Aggarwal | Chief Operating Officer | – | – | Apr 28, 2026 |
| Tod Smeal | Chief Scientific Officer | – | – | Apr 16, 2026 |
| Joshua B. Muntner | Chief Financial Officer | 500 | 0.00% | Apr 16, 2026 |
| Brigitte Ute Lindsay | Chief Accounting Officer | 27,431 | 0.04% | Feb 18, 2026 |
| Roger Sidhu | Chief Medical Officer | – | – | Jul 8, 2025 |
| Fairooz Kabbinavar | Chief Medical Officer | – | – | Mar 13, 2025 |
| James E. Levine | Chief Financial Officer | 127,716 | 0.16% | Mar 13, 2025 |
| Gary W. Pace | Director | 3,389,337 | 4.36% | Jul 16, 2026 |
| Renee P. Tannenbaum | Director | 20,000 | 0.03% | Jun 15, 2026 |
| James O. Armitage | Director | 27,490 | 0.04% | Jun 15, 2026 |
| Lale White | Director | 113,788 | 0.15% | Jun 15, 2026 |
| Rodney S. Markin | Director | 31,060 | 0.04% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mani Mohindru Chief Executive Officer, Director | Jul 14, 2026 | Buy | +34,364 | $1.46 | $50.17K | 59,067 |
| Gary W. Pace Director | Jul 14, 2026 | Buy | +687,285 | $1.46 | $1.00M | 2,043,661 |
| Gary W. Pace Director | Jun 18, 2026 | Buy | +30,000 | $1.22 | $36.60K | 1,356,376 |
| Mani Mohindru Chief Executive Officer, Director | Jun 18, 2026 | Buy | +24,703 | $1.21 | $29.89K | 24,703 |
| Gary W. Pace Director | Jul 30, 2025 | Buy | +15,000 | $2.45 | $36.75K | 1,345,676 |
| Gary W. Pace Director | Jul 30, 2025 | Buy | +275,000 | $2.45 | $673.75K | 1,330,676 |
| James E. Levine Chief Financial Officer | Dec 18, 2024 | Buy | +2,400 | $5.00 | $12.00K | 67,716 |
| James E. Levine Chief Financial Officer | Dec 17, 2024 | Buy | +2,752 | $5.42 | $14.92K | 65,316 |
| James E. Levine Chief Financial Officer | Dec 16, 2024 | Buy | +2,564 | $3.83 | $9.82K | 62,564 |
| Renee P. Tannenbaum Director | Dec 12, 2024 | Buy | +10,000 | $3.42 | $34.20K | 20,000 |
| Gary W. Pace Director | Dec 11, 2024 | Buy | +350,115 | $2.60 | $910.30K | 1,047,876 |
| Gary W. Pace Director | Dec 11, 2024 | Buy | +11,500 | $2.60 | $29.90K | 1,059,376 |
| Gary W. Pace Director | Dec 19, 2023 | Buy | +30,000 | $1.37 | $41.10K | 697,761 |
| Gary W. Pace Director | Nov 10, 2023 | Buy | +22,950 | $0.98 | $22.49K | 667,761 |
| Mark Erlander Chief Executive Officer, Director | Nov 25, 2022 | Buy | +10,000 | $1.43 | $14.30K | 24,481 |
| Lale White Director | Sep 19, 2022 | Buy | +15,000 | $1.64 | $24.60K | 113,788 |
| James O. Armitage Director | Sep 16, 2022 | Buy | +13,000 | $1.56 | $20.28K | 13,000 |
| James E. Levine Chief Financial Officer | Sep 16, 2022 | Buy | +30,000 | $1.56 | $46.80K | 60,000 |
| Renee P. Tannenbaum Director | Sep 15, 2022 | Buy | +3,600 | $1.72 | $6.19K | 10,000 |
| Renee P. Tannenbaum Director | Sep 15, 2022 | Buy | +6,400 | $1.72 | $11.01K | 6,400 |
| Gary W. Pace Director | Sep 15, 2022 | Buy | +150,000 | $1.71 | $256.50K | 644,811 |
| Lale White Director | Jul 5, 2022 | Option exercise | +28,858 | $2.60 | $75.03K | 98,788 |
| Gary W. Pace Director | Sep 21, 2021 | Buy | +30,000 | $6.75 | $202.50K | 494,811 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.32 | $31.60K | 30,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.35 | $31.75K | 25,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +10,000 | $6.38 | $63.80K | 20,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.75 | $33.75K | 10,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.62 | $33.10K | 5,000 |
| Rodney S. Markin Director | Mar 26, 2021 | Buy | +2,900 | $10.32 | $29.93K | 23,879 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +5,000 | $10.20 | $51.00K | 459,811 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +2,500 | $10.31 | $25.78K | 464,811 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +2,500 | $10.21 | $25.53K | 462,311 |
| Vicki Kelemen Exec. VP and COO | Mar 23, 2021 | Buy | +960 | $10.31 | $9.90K | 6,053 |
| Gary S. Jacob Director | Mar 23, 2021 | Buy | +1,900 | $10.42 | $19.80K | 21,452 |
| Gary S. Jacob Director | Mar 23, 2021 | Buy | +470 | $10.40 | $4.89K | 21,922 |
| Mark Erlander Chief Executive Officer | Mar 23, 2021 | Buy | +965 | $10.34 | $9.98K | 14,481 |
| John P. Brancaccio Director | Mar 22, 2021 | Buy | +3,000 | $10.95 | $32.85K | 12,260 |
| James O. Armitage Director | Mar 19, 2021 | Buy | +4,000 | $10.82 | $43.28K | 14,490 |
| Gary W. Pace Director | Mar 18, 2021 | Buy | +2,000 | $10.54 | $21.08K | 454,811 |
| Gary W. Pace Director | Mar 18, 2021 | Buy | +1,000 | $10.58 | $10.58K | 452,811 |
| Gary W. Pace Director | Mar 4, 2021 | Buy | +1,500 | $9.27 | $13.91K | 451,811 |
| Mark Erlander Chief Executive Officer | Jan 2, 2021 | Tax withholding | −113 | – | – | 13,516 |
| Mark Erlander Chief Executive Officer | Jan 2, 2021 | Option exercise | +260 | – | – | 13,629 |
| Vicki Kelemen Exec. VP and COO | Jan 2, 2021 | Tax withholding | −31 | – | – | 5,093 |
| Vicki Kelemen Exec. VP and COO | Jan 2, 2021 | Option exercise | +70 | – | – | 5,124 |
| Vicki Kelemen Exec. VP and COO | Nov 23, 2020 | Sale | −35,321 | $18.60 | $656.97K | 5,054 |
| Vicki Kelemen Exec. VP and COO | Nov 23, 2020 | Option exercise | +35,321 | $2.48 | $87.60K | 40,375 |
| Gary W. Pace Director | Sep 16, 2020 | Buy | +1,700 | $5.69 | $9.67K | 449,461 |
| Gary W. Pace Director | Sep 16, 2020 | Buy | +850 | $5.71 | $4.85K | 450,311 |
| James O. Armitage Director | May 14, 2020 | Buy | +10,490 | $1.43 | $15.00K | 10,490 |
| Mark Erlander Chief Executive Officer | May 14, 2020 | Buy | +6,993 | $1.43 | $10.00K | 13,369 |
| Rodney S. Markin Director | May 14, 2020 | Buy | +20,979 | $1.43 | $30.00K | 28,160 |
| Lale White Director | May 14, 2020 | Buy | +69,930 | $1.43 | $100.00K | 69,930 |
| John P. Brancaccio Director | May 14, 2020 | Buy | +6,993 | $1.43 | $10.00K | 9,260 |
| Gary S. Jacob Director | May 14, 2020 | Buy | +17,483 | $1.43 | $25.00K | 19,552 |
| Thomas Adams Phd Director | May 14, 2020 | Buy | +13,986 | $1.43 | $20.00K | 18,875 |
| Gary W. Pace Director | May 11, 2020 | Buy | +447,761 | $1.34 | $600.00K | 447,761 |
| Mark Erlander Chief Scientific Officer | Jan 3, 2020 | Tax withholding | −116 | – | – | 6,376 |
| Mark Erlander Chief Scientific Officer | Jan 3, 2020 | Tax withholding | −552 | – | – | 6,231 |
| Mark Erlander Chief Scientific Officer | Jan 2, 2020 | Option exercise | +261 | – | – | 6,492 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.